http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110498784-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-22 |
| filingDate | 2019-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110498784-B |
| titleOfInvention | Nobiletin derivatives or pharmaceutically acceptable salts thereof, and preparation method and application thereof |
| abstract | The invention discloses a nobiletin derivative or a pharmaceutically acceptable salt thereof, and a preparation method and application thereof. The structure of the nobiletin derivative is shown as a formula (I); wherein R is 1 、R 2 、R 3 And R 4 Are respectively selected from hydrogen, halogen, hydroxyl, amino and C 1‑6 Substituted or unsubstituted alkoxy, C 1‑6 Substituted or unsubstituted ester group, C 1‑6 Substituted or unsubstituted alkylamino, C 1‑6 A substituted or unsubstituted amide group; r 5 Is selected from C 3‑9 Substituted or unsubstituted aromatic ring, C 3‑9 Substituted or unsubstituted aromatic heterocyclic ring; x is selected from O or NR 6 . The nobiletin derivative or the pharmaceutically acceptable salt thereof has a novel structure, and the compound has excellent inhibitory action on P-gp, can be prepared into a P-gp inhibitor for use, and can be used for treating and/or preventing related diseases caused by P-gp, particularly diseases related to tumor drug resistance; or mixed with other medicines for use, and is used as a drug resistance reversal agent, the reversal multiple is high, and the drug effect of the medicine can be obviously improved. |
| priorityDate | 2019-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.